TcLand Expression signs a licensing agreement with Inserm Transfert

Strategic collaboration on the development of companion diagnostic tests for rheumatoid arthritis therapies

08-Jul-2010 - France

TcLand Expression SA announced the signature of a licensing agreement with Inserm Transfert. The terms of the agreement include the grant of worldwide, exclusive licenses to TcLand Expression for two different patents covering gene expression signatures which can predict responsiveness to rheumatoid arthritis (RA) therapies.

TcLand Expression is developing and clinically validating gene-expression-based biomarkers in the field of transplantation and companion diagnostic tests for use with auto-immune disease therapies. Based on the methods protected by the two Inserm patents, TcLand Expression intends to develop companion diagnostic tests for RA therapies. The signature of this agreement marks the start of close collaboration between the two organizations because TcLand Expression's researchers will cooperate with the joint Inserm/University of Rouen U905 "Physiopathology and Biotherapy of Inflammatory and Autoimmune Disease" research unit (headed by Professor Olivier Boyer).

"This agreement is much more than a simple licensing deal because it means that our R&D division will collaborate closely with Inserm researchers on the design of companion diagnostics for treatment of RA - a severe, disabling disease which affects some 70 million people worldwide!", commented TcLand Expression CEO Alain Huriez. "Our company has forged a number of strategic collaborations for the development of new biomarkers in this disease area - not only with the Inserm but also with the Vall d'Hebron University Hospital Research Institute in Spain and the Lyons Public Hospitals Group in France", he concluded.

https://www.bionity.com/en/news/119789/tcland-expression-signs-a-licensing-agreement-with-inserm-transfert.html